Ra Capital Management, L.p. sold $58M of FULC
owner at Fulcrum Therapeutics, Inc.. 4,175,139 shares at an average of $13.98, traded Dec 8, 2025, filed Dec 10, 2025.
Score components
- +12Role10% owner
- +25Trade size$58.4M at market
- +10Share of holdings soldSold 41% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -28.6%, 3m -43.6%, 6m -74.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-25-000596, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 8, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -1,377,020 | $13.33 | $18M | 8,852,079 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -2,706,397 | $14.28 | $39M | 6,145,682 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -91,722 | $14.98 | $1.4M | 6,053,960 | Dec 10, 2025 |
Related signals
Other insiders at Fulcrum Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 49Moderate | FULCbuy Fulcrum Therapeutics, Inc. | Kevin C Tang owner | $595k 167,616 shares | +2% | |
| 48Moderate | FULCbuy Fulcrum Therapeutics, Inc. | Kevin C Tang owner | $891k 249,946 shares | +4% | |
| 23Weak | Fulcrum Therapeutics, Inc. | Alan Ezekowitz director | $66k 18,000 shares | -62% | |
| 6Weak | Fulcrum Therapeutics, Inc. | Robert J Gould director | $161k 15,000 shares | -3% | |
| 6Weak | Fulcrum Therapeutics, Inc. | Robert J Gould director | $163k 15,000 shares | -3% | |
| 7Weak | Fulcrum Therapeutics, Inc. | Robert J Gould director | $178k 15,000 shares | -3% | |
| 19Weak | Fulcrum Therapeutics, Inc. | Curtis Gale Oltmans Chief Legal Officer | $45k 3,452 shares | -25% | |
| 6Weak | Fulcrum Therapeutics, Inc. | Robert J Gould director | $165k 15,000 shares | -3% | |
| 15Weak | FULCsell Fulcrum Therapeutics, Inc. | Greg Tourangeau Principal Accounting Officer | $2,520 498 shares | -3% | |
| 15Weak | FULCsell Fulcrum Therapeutics, Inc. | Greg Tourangeau Principal Accounting Officer | $1,831 236 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.